Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Advexin demonstrates clinical benefit of new LFS treatment

Introgen Therapeutics : 30 May, 2007  (New Product)
Introgen Therapeutics has announced the publication of data that outlines the clinical benefits of Advexin in a patient with a rare inherited form of of cancer known as Li-Fraumeni Syndrome (LFS).
LFS is a genetic disorder characterised by inherited mutations in the p53 tumour suppressor gene.

This is the first reported treatment of Li-Fraumeni tumours with a therapy targeted to the underlying molecular cause of the disorder.

These cancers are due to inherited abnormalities of p53 function which is directly addressed by Advexin treatment.

In addition, the results of the study evaluated biomarkers which confirmed the molecular mechanism of activity of Advexin.

These biomarkers will guide Advexin therapy of other cancers with p53 abnormalities, which is one of the most common molecular defects found in virtually all types of cancer.

The patient was treated as part of a study at the Mary Crowley Medical Research Center in Dallas, Texas, USA.

Advexin treatment of a tumour in an LFS patient led to improvement of tumour-related symptoms and resulted in a complete response as determined by positron emission tomography (PET) scans.

In addition, molecular Biomarker studies using tumour biopsies before treatment detected abnormal levels of p53 protein predictive of Advexin efficacy.

Tumour biopsies analysed after therapy identified restoration of p53 tumour suppressor function including suppression of tumour growth and induction of tumour cell death validating Advexin's mechanisms of action.

'This case study showcases and provides proof of the principle for the therapeutic application of targeted Advexin therapy in tumours with p53 abnormalities that are among the most common and fundamental molecular defects in cancer', said Neil Senzer, MD, scientific director, Mary Crowley Medical Research Center, and lead author of the article.

'Advexin's mechanism of action is targeted to restoring p53 tumour suppressor function that is abnormal in Li-Fraumeni tumours and in many other types of cancer'.

Advexin is being developed for European markets by Gendux, a subsidiary of Introgen Therapeutics The European Medicines Agency (EMEA) has designated, and the European Union has confirmed, Advexin p53 therapy as an Orphan Drug for the treatment of LFS.

A Letter of Intent to the EMEA regarding Marketing Authorization Application for the approval of Advexin to treat LFS was filed under the Exceptional Circumstances Approval procedures in the EU.

Collaborators on this publication included clinicians from Mary Crowley Medical Research Center, Sammons Cancer Center, Baylor University Medical Center, The Royal Marsden Hospital NHS Foundation Trust, Imperial College London Hammersmith Campus, and the Institute of Cancer Research in the United Kingdom.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo